DEXTENZA® (dexamethasone ophthalmic insert)

DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.1

Please see Important Safety Information below.

DEXTENZA provides an opportunity for physicians to alleviate their patients of the burden of administration of their post-op steroid drop regimen.2 One of our innovative inserts can replace the need for patients to administer ~70 steroid eye drops.3

DEXTENZA is a preservative-free intracanalicular insert that is inserted in the lower lacrimal punctum, a natural opening in the eye lid, and into the canaliculus.1 DEXTENZA is designed to deliver a tapered dose of steroid (dexamethasone) to the ocular surface for up to 30 days.1,4 Following treatment, DEXTENZA resorbs and exits the nasolacrimal system without the need for removal.1

Click here to visit


Video courtesy of Dr. Joe Gira.



DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.


Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment.

Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.


The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%); intraocular pressure increased (6%); visual acuity reduced (2%); eye pain (1%); cystoid macular edema (1%); corneal edema (1%); and conjunctival hyperemia (1%).

The most common non-ocular adverse reaction that occurred in patients treated with DEXTENZA was headache (1%).

Please see full Prescribing Information.

DEXTENZA is dexamethasone delivered via hydrogel technology1,2


  • With moisture
  • Swells to fit comfortably and securely in the canaliculus


  • Dexamethasone for up to 30 days


  • Slowly through the course of treatment
  • Clears via the nasolacrimal duct

REFERENCES: 1. DEXTENZA (dexamethasone ophthalmic insert) [prescribing information]. Bedford, MA: Ocular Therapeutix, Inc; 2019. 2. Walters T, et al. J Clin Exp Ophthalmol. 2016;7(4):1-11. 3. Data on file 00663. Ocular Therapeutix, Inc. 4. Sawhney AS, et al. US patent 8,409,606 B2. April 2, 2013.